Abstract
Cytochrome P450 (CYP450) enzymes have the capability of playing key metabolic roles in several aspects of cancer as a consequence of their unusually broad substrate specificities. CYP450 are also prominent players in the metabolism of anticancer therapeutic drugs, enhancing or diminishing the efficacy of the drugs depending on whether the drug or its metabolites are efficacious. As CYP450 enzymes are also found in lung tissue, lung metabolism can be of importance to the bioactivation of some anticancer agents. The presence of individual forms of CYP450 has been investigated in lung tumor to determine whether intra-tumor metabolism of anticancer agents by CYP450 could occur and thus influence the response of tumor to these agents. Differences in drug metabolism between normal and cancerous lung tissue have been shown to exist, therefore; the variable expression of CYP450 between tumor and normal tissue can provide a basis for selective sensitivity of tissue to anticancer drugs, thereby localizing drug actions to tumor. This review gives a detailed picture of the expression of CYP450 in lung tumor and the role of this enzyme in lung tumor in the fate of anticancer drugs.
Keywords: anticancer drugs, cytochrome p450, drug metabolizing enzymes, cancer, lung, tumor
Current Drug Metabolism
Title: Expression of Cytochrome P450 in Lung Tumor
Volume: 5 Issue: 2
Author(s): Negar Gharavi and Ayman O.S. El-Kadi
Affiliation:
Keywords: anticancer drugs, cytochrome p450, drug metabolizing enzymes, cancer, lung, tumor
Abstract: Cytochrome P450 (CYP450) enzymes have the capability of playing key metabolic roles in several aspects of cancer as a consequence of their unusually broad substrate specificities. CYP450 are also prominent players in the metabolism of anticancer therapeutic drugs, enhancing or diminishing the efficacy of the drugs depending on whether the drug or its metabolites are efficacious. As CYP450 enzymes are also found in lung tissue, lung metabolism can be of importance to the bioactivation of some anticancer agents. The presence of individual forms of CYP450 has been investigated in lung tumor to determine whether intra-tumor metabolism of anticancer agents by CYP450 could occur and thus influence the response of tumor to these agents. Differences in drug metabolism between normal and cancerous lung tissue have been shown to exist, therefore; the variable expression of CYP450 between tumor and normal tissue can provide a basis for selective sensitivity of tissue to anticancer drugs, thereby localizing drug actions to tumor. This review gives a detailed picture of the expression of CYP450 in lung tumor and the role of this enzyme in lung tumor in the fate of anticancer drugs.
Export Options
About this article
Cite this article as:
Gharavi Negar and El-Kadi O.S. Ayman, Expression of Cytochrome P450 in Lung Tumor, Current Drug Metabolism 2004; 5 (2) . https://dx.doi.org/10.2174/1389200043489045
DOI https://dx.doi.org/10.2174/1389200043489045 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Therapies for Advanced Non-Small Cell Lung Cancer
Combinatorial Chemistry & High Throughput Screening Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation
Medicinal Chemistry FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes
Current Radiopharmaceuticals Internalization and Intracellular Trafficking of Poly(propylene imine) Glycodendrimers with Maltose Shell in Melanoma Cells
Current Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Promoters - Microcystin-LR, Nodularin and TNF-α and Human Cancer Development
Anti-Cancer Agents in Medicinal Chemistry Analysis of Oxaliplatin Resistance in Colorectal Cancer Cells by Combined Proteomics and Phosphoproteomic
Current Proteomics Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship
Current Medicinal Chemistry Cell-in-cell phenomenon: A New Paradigm in Life Sciences.
Current Molecular Medicine MicroRNAs as Therapeutic Targets for Anticancer Drugs in Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets